The Promotion of Drug Innovation in Italy: Critical Aspects and Unsolved Problems

F. Mennini, L. Gitto, R. Scrivo, F. Drago, Marco Iezzi, L. Terranova, M. Ruggeri, A. Marcellusi, S. Russo, R. Viti, A. Cicchetti
{"title":"The Promotion of Drug Innovation in Italy: Critical Aspects and Unsolved Problems","authors":"F. Mennini, L. Gitto, R. Scrivo, F. Drago, Marco Iezzi, L. Terranova, M. Ruggeri, A. Marcellusi, S. Russo, R. Viti, A. Cicchetti","doi":"10.5301/GRHTA.5000216","DOIUrl":null,"url":null,"abstract":"The pharmaceutical sector is characterized by the level of investments required in response to the growing challenges in terms of demand for health.In most European countries the pharmaceutical industry, through production, research, intermediate goods and wages, contributes to GDP for a value of about 1%. The impact of the pharmaceutical industry on the added value varies from 23 billion euro in Switzerland to 9.6 billion euro in Spain; for Italy, this value is about 14 billion euro, higher than the average of other European countries.However, despite these positive findings, Italy can hardly keep up with other European countries in investments in R&D in the pharmaceutical sector.An even larger amount of resources is required by the development of personalized therapies and new generation drugs, e.g. developed through biotechnology, which are more effective in responding to complex health needs. Clear rules, aimed at defining and fostering innovation, together with competitive pricing models, are require...","PeriodicalId":228031,"journal":{"name":"Global and Regional Health Technology Assessment","volume":"29 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2016-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global and Regional Health Technology Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5301/GRHTA.5000216","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

The pharmaceutical sector is characterized by the level of investments required in response to the growing challenges in terms of demand for health.In most European countries the pharmaceutical industry, through production, research, intermediate goods and wages, contributes to GDP for a value of about 1%. The impact of the pharmaceutical industry on the added value varies from 23 billion euro in Switzerland to 9.6 billion euro in Spain; for Italy, this value is about 14 billion euro, higher than the average of other European countries.However, despite these positive findings, Italy can hardly keep up with other European countries in investments in R&D in the pharmaceutical sector.An even larger amount of resources is required by the development of personalized therapies and new generation drugs, e.g. developed through biotechnology, which are more effective in responding to complex health needs. Clear rules, aimed at defining and fostering innovation, together with competitive pricing models, are require...
促进意大利的药物创新:关键方面和未解决的问题
制药部门的特点是需要大量投资,以应对保健需求方面日益增长的挑战。在大多数欧洲国家,制药业通过生产、研究、中间产品和工资,对GDP的贡献约为1%。制药业对增加值的影响从瑞士的230亿欧元到西班牙的96亿欧元不等;意大利的这一价值约为140亿欧元,高于其他欧洲国家的平均水平。然而,尽管有这些积极的发现,意大利在制药部门的研发投资方面很难跟上其他欧洲国家。开发个性化疗法和新一代药物,例如通过生物技术开发的新一代药物,需要更多的资源,这些药物在应对复杂的保健需要方面更有效。我们需要明确的规则,旨在界定和促进创新,以及具有竞争力的定价模式。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信